CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE) a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that data from clinical studies of its proprietary i.v. formulation of brexanolone for the treatment of postpartum depression (PPD) as well as SAGE-217, its novel, next-generation positive allosteric modulator of synaptic and extrasynaptic GABAA receptors, in major depressive disorder (MDD), will be presented in podium and poster sessions at the following upcoming medical meetings:
North American Society for Psychosocial
Obstetrics and Gynecology (NASPOG)
2018 Biennial
Meeting, April 20-22, 2018 in Philadelphia
- Date and Time: April 20, 2018, 12:15 p.m. – 1:15 p.m. ET
- Location: University of Pennsylvania Biomedical Research Building
- Title: Brexanolone iv, a GABAA Receptor Modulator, in the Treatment of Postpartum Depression: Overview of Clinical Studies
American College of Obstetricians and
Gynecologists (ACOG)
2018 Annual Clinical and Scientific
Meeting, April 27-30, 2018 in Austin, Texas
- Date and Time: April 27, 2018, 1:00 p.m. – 2:00 p.m. CT
- Location: Austin Convention Center, Ballroom G
-
Title: Phase 3 Study Evaluating Brexanolone, a GABAA
Receptor Modulator, in Severe Postpartum Depression
- Date and Time: April 28, 2018, 10:15 a.m. – 11:15 a.m. CT
- Location: Austin Convention Center, Ballroom G
- Title: Phase 3 Study Evaluating Brexanolone, a GABAA Receptor Modulator, in Moderate Postpartum Depression
American Psychiatric Association (APA)
2018
Annual Meeting, May 5-9, 2018 in New York
- Date and Time: May 7, 2018, 10:00 a.m. – 12:00 p.m. ET
- Location: Exhibit Halls 3A/3B, Level 3
-
Title: Efficacy and Safety of Brexanolone iv in Hummingbird
202B: A Double-Blind, Placebo-Controlled Phase 3 Study in Severe
Postpartum Depression
- Date and Time: May 7, 2018, 10:00 a.m. – 12:00 p.m. ET
- Location: Exhibit Halls 3A/3B, Level 3
-
Title: Efficacy and Safety of Brexanolone iv in Hummingbird
202C: A Double-Blind, Placebo-Controlled Phase 3 Study in Moderate
Postpartum Depression
- Date and Time: May 7, 2018, 10:00 a.m. – 12:00 p.m. ET
- Location: Exhibit Halls 3A/3B, Level 3
- Title: SAGE-217 in Major Depressive Disorder: Results for a First-in-Class GABAA Receptor Allosteric Modulator from a Phase 2 Placebo-Controlled Trial
Society of Biological Psychiatry (SOBP)
73rd
Annual Meeting, May 10-12, 2018 in New York
- Date and Time: May 12, 2018, 5:00 p.m. – 7:00 p.m. ET
- Location: Americas Hall I
-
Title: Efficacy and Safety of Brexanolone iv across Phase
2/3 Studies: A First-In-Class GABAA Receptor
Positive Allosteric Modulator for Postpartum Depression
- Date and Time: May 12, 2018, 4:15 p.m. – 4:30 p.m. ET
- Location: Murray Hill East
- Title: SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial
About Sage Therapeutics
Sage Therapeutics is a
clinical-stage biopharmaceutical company committed to developing novel
medicines to transform the lives of patients with life-altering central
nervous system (CNS) disorders. Sage has a portfolio of novel product
candidates targeting critical CNS receptor systems, GABA and NMDA.
Sage's lead program, a proprietary IV formulation of brexanolone
(SAGE-547), has completed Phase 3 clinical development for postpartum
depression. Sage is developing its next generation modulators, including
SAGE-217 and SAGE-718, in various CNS disorders. For more information,
please visit www.sagerx.com.